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OBJECTIVES The study compared the prognostic value of dipyridamole and dobutamine stress echocar-
diography in patients with known or suspected coronary artery disease.
BACKGROUND Extensive information is available on the relative diagnostic accuracy of the two tests assessed
in a head-to-head fashion, whereas comparative data on their prognostic yield are largely
preliminary to date.
METHODS Dipyridamole (up to 0.84 mg/kg over 10 min) atropine (up to 1 mg over 4 min) (DIP) and
dobutamine (up to 40 mg/kg/min)-atropine (1 mg over 4 min) (DOB) stress tests were
performed in 460 patients with known or suspected coronary artery disease. Patients were
followed up for 38 6 21 months.
RESULTS The DIP was negative in 253 and positive in 207 patients. The DOB was negative in 242 and
positive in 218 patients. During the follow-up, there were 80 cardiac events. For all cardiac
events, the negative and positive predictive value were 83% and 17% for DOB, 84% and 19%
for DIP, respectively (p 5 NS). Considering only cardiac death, by univariate analysis
Wall-Motion Score Index (WMSI) at DIP peak dose (chi-square 13.80, p , 0.0002) was the
strongest predictor, followed by WMSI DOB (x2 5 8.02, p , 0.004) and WMSI at rest
(x2 5 6.85, p , 0.008). By stepwise analysis, WMSI at DIP peak dose was the most
important predictor (RR [relative risk] 7.4, p , 0.0001).
CONCLUSIONS In patients at low-to-moderate risk of cardiac events, pharmacological stress echocardiogra-
phy with either dobutamine or dipyridamole allows effective and grossly comparable, risk
stratification on the basis of the presence, severity and extension of the induced ischemia.
(J Am Coll Cardiol 1999;34:1769–77) © 1999 by the American College of Cardiology
According to the recent guidelines of the American College
of Cardiology/American Heart Association (ACC/AHA)
pharmacological stress echocardiography with either dobut-
amine or dipyridamole is a class 1 indication (of docu-
mented effectiveness and usefulness) for the diagnosis of
coronary artery disease and for the prognostic stratification
of patients with known coronary artery disease (1). The
American Society of Echocardiography has also recom-
mended pharmacological stress echocardiography with ei-
ther dobutamine or dipyridamole as the preferred modality
in patients who cannot exercise (2). The choice of one
pharmacological test over the other as the preferred imaging
echocardiographic modality may depend upon local drug
cost, test safety, and information provided in terms of
diagnostic accuracy and prognostic stratification (3). Exten-
sive information is available on the relative diagnostic
accuracy of the two tests assessed in a head-to-head fashion
(4–13), whereas comparative data on their prognostic yield
are largely preliminary to date (13,14), encompassing only
two studies (13,14) totaling 184 patients. These studies
showed a similar prognostic value of the two tests, but
suffered some limitations: “state of the art” protocols (high
dose with atropine coadministration) were not used; soft
events, such as revascularization procedures, had to be
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included as meaningful end points owing to the very low
incidence of hard events; patient population was strictly
selected and enrolled in single centers, possibly not repre-
senting the full spectrum of patients arriving to the stress
echocardiography laboratory. The purpose of this study was
to compare, head-to-head, the prognostic value of dipyrid-
amole and dobutamine stress echocardiography in patients
with known or suspected coronary artery disease in a
large-scale, multicenter, observational and prospective study
design on the basis of evidence collected by 14 different
echocardiographic laboratories. All laboratories had an es-
tablished experience in stress echocardiography, met the
quality-control requirements for stress echocardiographic
interpretation before starting patient enrollment, and be-
longed to the stress echocardiographic network of the EPIC
(Echo Persantine International Cooperative) and EDIC
(Echo Dobutamine International Cooperative) studies.
METHODS
Patients. From the EPIC and EDIC data bank, 538
patients (510 men, mean age 60 6 12 years) who had
performed both dipyridamole-atropine (DIP) and
dobutamine-atropine (DOB) stress echocardiography were
initially selected. Of these, 37 patients were excluded
because the two tests were performed within a time interval
.15 days; 18 patients performed the two tests under
different therapeutic conditions and an additional 23 pa-
tients were lost to follow-up. Therefore, the final population
consisted of 460 patients (379 men, mean age 60 6 10
years) with known or suspected coronary artery disease. Of
these 460 patients, 171 had a recent (,10 days) uncompli-
cated myocardial infarction; 108 had a previous (.3
months) myocardial infarction; 155 had angina pectoris and
26 complained of atypical chest pain. Each patient per-
formed dipyridamole and dobutamine stress testing on
different days, in random order, and within 15 days. A total
of 206 patients performed dipyridamole first and 254
patients performed dobutamine first. Three hundred fifty-
eight patients were off therapy at the time of testing; 82
underwent both testing under identical antianginal therapy,
which consisted of nitrates in 21, calcium antagonists in 15,
beta-adrenergic blocking in 13, and combined therapy in 33
cases (nitrates and calcium antagonists in 17 and nitrates
and beta blockers in 16 cases). Verbal informed consent to
undergo two stress tests was obtained from all patients.
Stress echocardiographic protocols. DOBUTAMINE-
ATROPINE. Dobutamine was infused in 3-min dose incre-
ments, starting from 5 mg/kg/min and increased to 10, 20,
30, and 40 mg/kg/min (10,15). When no end point was
reached, atropine (in four divided doses of 0.25 mg up to a
maximum of 1 mg) was added to the continuing 40
mg/kg/min dobutamine infusion.
DIPYRIDAMOLE-ATROPINE. Dipyridamole was infused in-
travenously at a dose of 0.56 mg/kg body weight over 4 min,
followed by 4 min of no dose and then, if the test was still
negative, 0.28 mg/kg over 2 min. When no end point was
reached at 3 min after the end of dipyridamole infusion,
atropine (in four divided doses of 0.25 mg up to a maximum
of 1 mg) was given (16).
Echocardiographic analysis. Two-dimensional echocar-
diographic monitoring was performed throughout and up to
10 min after stopping the drug infusion. Two-dimensional
images were recorded at baseline and at the end of each step.
Regional wall-motion analysis was evaluated at baseline and
at peak stress with a semiquantitative assessment of a
Wall-Motion Score Index (WMSI), with the 16-segment
model of the left ventricle, each segment ranging from 1 5
normal/hyperkinetic to 4 5 dyskinetic, according to recom-
mendations of the American Society of Echocardiography
(17). The WMSI was derived by dividing the sum of
individual segment scores by the number of interpretable
segments (17). Test positivity was defined as the occurrence
of at least one of the following conditions: 1) new dyssyn-
ergia in a region with normal rest function (i.e., normoki-
nesia becoming hypokinesia, akinesia or dyskinesia); 2)
worsening of rest dyssynergy (i.e., hypokinesia becoming
akinesia or dyskinesia). Resting akinesia becoming dyskine-
sia was not considered a criterion of positivity, because this
can result from passive stretching phenomena rather than
from active ischemia (18). The extension and severity of
induced ischemia was expressed as a Delta WMSI: a
variation between the resting WMSI and peak WMSI
without considering functional recovery of basally asynergic
segments.
Furthermore, the extension of induced ischemia was also
expressed as the number of ischemic segments at peak stress.
Nonechocardiographic test end points were the following
(10): peak atropine dose; 85% of target heart rate; achieve-
ment of conventional end points (such as severe chest pain
and/or diagnostic ST segment changes). The test was also
stopped, in the absence of diagnostic end points, for one of
the following reasons of submaximal, nondiagnostic test
(10): intolerable symptoms; limiting asymptomatic side
effects, consisting of a) hypertension (systolic blood pressure
.220 mm Hg; diastolic blood pressure .120 mm Hg); b)
hypotension (relative or absolute): .30 mm Hg fall of blood
pressure; c) supraventricular arrhythmias: supraventricular
tachycardia or atrial fibrillation; d) ventricular arrhythmias:
ventricular tachycardia; frequent, polymorphous premature
ventricular beats.
Abbreviations and Acronyms
DIP 5 dipyridamole-atropine
DOB 5 dobutamine-atropine
EDIC 5 Echo Dobutamine International Cooperative
EPIC 5 Echo Persantine International Cooperative
RR 5 relative risk
WMSI 5 Wall-Motion Score Index
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Quality control of stress echocardiographic readings.
Quality control of the diagnostic performance in the differ-
ent centers was of critical importance in acquiring mean-
ingful information into the data bank. In the enrolled
centers, the quality control was performed based upon two
criteria, each one having to be met to fulfill the quality-
control requirements (19).
The first criterion was tested on a videotape with 20 stress
echocardiographic studies prepared in the coordinating
center (Institute of Clinical Physiology in Pisa, Italy). In all
these 20 studies the reading of two experienced independent
observers was concordant as to presence and site of dyssyn-
ergy, and the stress results were in full agreement with
presence and site of coronary stenoses during coronary
angiography. The unanimous reading of the two observers
was arbitrarily assumed to be the “gold standard” against
which to evaluate the reading of each participating center.
The reader from each center interpreted the videotape in a
blinded fashion, with no access either to clinical and
angiographic data or to the interpretation given by other
observers. It was assumed a priori that the minimum
threshold of concordance to pass this part of the quality
control had to be 90%. The second criterion consisted in
random-sampling 20 consecutive studies from each contrib-
uting center. These 20 studies were examined in a blinded
fashion by an experienced cardiologist-echocardiographist
of the coordinating center and whose reading was arbitrarily
assumed to be the “gold standard.” It was assumed a priori
that the minimum threshold of concordance to pass the
quality control had to be 80%. The lower concordance cutoff
in comparison with the first type of reading was due to the
fact that this second set of tapes was not selected on the
basis of the superior quality but randomly sampled from
each center in a consecutive fashion. All 14 enrolled centers
met the minimum requirements of quality control.
Follow-up data. The follow-up data were obtained from at
least one of four sources: review of the patient’s hospital
record; personal communication with the patient’s physician
and review of the patient’s chart; a telephone interview with
the patient conducted by trained personnel; a staff physician
visiting the patients at regular intervals in the outpatient
clinic (19). Events were defined as cardiac-related deaths,
nonfatal myocardial infarction, and revascularization proce-
dures. For patients who died in the hospital or at home, the
cause of death was elucidated from the medical record, from
the family, and from the local physician who signed the
death certificate. The definition of cardiac-related death
required documentation of significant arrhythmias or car-
diac arrest, or both, or death attributable to congestive heart
failure or myocardial infarction in the absence of any other
precipitating factors. In case of death out of hospital for
which no autopsy was performed, sudden unexpected death
was attributed to a cardiac cause. Myocardial infarction was
defined as a cardiac event requiring hospital admission to
the hospital, with development of new electrocardiograph
(ECG) changes and cardiac enzyme-level increases. Revas-
cularization procedures were considered only when they had
been performed three months after the tests. Test results
were available to the referring physician who was responsi-
ble for the decision to submit a patient to a revascularization
procedure. As always, this decision was made after consid-
ering all the clinical, echocardiographical, and angiographic
variables.
Statistical analysis. Values are expressed as mean 6 stan-
dard deviation. The individual effect of certain variables on
event-free survival was evaluated with the use of the Cox
regression model (BMDP 2L, Department of Biomathe-
matics, University of California at Los Angeles, revised
1987). The analysis was performed according to the unmod-
ified forward selection stepwise procedure. In this case, the
variables were entered in the model on the basis of a
computed significance probability; accordingly, the variable
that has the most significant relation to dependent outcome
is selected first for inclusion in the model, and a solution to
the functional form of the equation is computed. At the
second and subsequent steps, the set of variables remaining
at each point is evaluated, and the most significant is
included if it improves the prediction of the outcome
(dependent variable), but in this case this probability was
conditional on the presence of the variable already selected.
The algorithm ceases to select variables when there is no
further significant improvement in the prediction of the
entire model. Selected variables were the following: age, sex,
history of angina, previous myocardial infarction, concom-
itant antianginal therapy, recent acute uncomplicated myo-
cardial infarction, previous angioplasty (history of PTCA;
percutaneous transluminal coronary angioplasty), previous
coronary artery bypass graft (CABG) surgery (history of
CABG), WMSI at rest (resting WMSI), dipyridamole and
dobutamine-atropine stress echocardiography positivity,
WMSI at peak dobutamine (DOB WMSI) and at peak
dipyridamole (DIP WMSI), Delta-WMSI of DIP and
DOB (Delta DIP and Delta DOB WMSI), number of
ischemic segments during DIP, number of ischemic seg-
ments during DOB, dipyridamole and dobutamine time
(i.e., test duration to time of echocardiographically detected
ischemia).
Continuous variables were compared by the paired two-
sample t test. Proportions were compared by the chi-square
statistic; the Fisher exact test was used when appropriate.
Kaplan-Meier survival curves event-free of cardiac death
were used to summarize the follow-up experience in these
patients and to clarify presentation. Differences of survival
curves were tested with the log-rank statistic. A p value
below 0.05 was considered statistically significant. Receiver-
operating characteristics analysis was used to determine the
optimal cutoff value for prediction of cardiac death with
respect to the DIP and DOB WMSI and the number of
ischemic segments during both tests. The best cutoff value
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was defined as the point with the highest sum of sensitivity
and specificity.
RESULTS
Feasibility and tolerability of DIP and DOB. One pa-
tient had sustained ventricular tachycardia during DOB
testing. Additional minor but limiting side effects occurred
in 36 DOB and 13 DIP patients, yielding an overall
feasibility of 92% and 97%, respectively (p , 0.005). The
test results of these patients were included in the analysis as
negative tests.
Stress echocardiographic findings. The resting WMSI
was 1.37 6 0.38 for the overall population. The DIP test
was negative in 253 and positive in 207 patients. Of the
positive tests, 73 were positive at low dose (#8 min), 90 at
high dose (.8 min up to 12 min), and 44 during or after
atropine infusion. The DOB test was negative in 242 and
positive in 218 patients. Of the positive tests, 99 were
positive at low dose (#12 min) and 92 at high dose
(.12 min up to 17 min), and 27 during or after atropine
infusion. The WMSI at peak dose increased up to 1.70 6
0.35 during DIP (p , 0.001 vs. rest WMSI) and up to
1.61 6 0.39 during DOB (p , 0.005 vs. rest WMSI). Delta
WMSI was 0.28 6 0.16 for DIP and 0.29 6 0.18 for DOB
(p 5 NS). According to a cutoff of 0.37, 57 patients had a
value of Delta WMSI higher than 0.37 with DIP and 56
with DOB.
Follow-up data. Patients were followed up for 38 6 21
months (range 1 to 82 months). Eighty-three patients
underwent revascularization procedure within three months
of stress testing (PTCA n 5 50, CABG n 5 33) and
therefore were censored. During the follow-up period, there
were 18 cardiac-related deaths, 22 acute nonfatal myocardial
infarctions and 40 revascularization procedures (angioplasty
n 5 17; coronary artery bypass graft n 5 23). All events
occurred in 41 of the 253 patients with negative and in 39
of the 207 patients with positive DIP (16% vs. 19%, p 5
NS). Among the subset with positive DIP, eight events
occurred in the 44 patients with atropine, 15 in the 90
patients with high dose and 16 in the 73 patients with low
dose positivity (18% vs. 16.6% vs. 22%, p 5 NS). Consid-
ering DOB, events occurred in 42 of the 242 patients with
negative and in 38 of the 218 patients with positive test
(16% vs. 19%, p 5 NS). Among the subset with positive
DOB, six events occurred in the 27 patients with atropine,
16 in the 92 with high dose and 16 in the 99 patients with
low dose positivity (22% vs. 17% vs. 16%, p 5 NS). The
relationship between all cardiac events and different stress-
test responses is shown in Table 1.
For all cardiac events, the negative predictive value was
83% for DOB and 84% for DIP (p 5 NS), and the positive
predictive value was 17% for DOB and 19% for DIP (p 5
NS). Considering only cardiac death, there were 12 events
in patients with positive and 6 events in those with negative
DIP (5.7% vs. 2.3%, p 5 NS). Considering DOB, 10
cardiac deaths were in patients with positive and 8 in those
with negative DOB (4.5% vs. 3.3%, p 5 NS). By univariate
analysis, DIP WMSI (chi-square 13.80, p , 0.0002) was
the strongest predictor. The other independent predictors
are shown in Table 2. By stepwise analysis, DIP WMSI was
the most important predictor followed by previous angio-
plasty; see Table 3. For cardiac death, the negative predic-
tive value was 96% for DOB and 97% for DIP (p 5 NS),
and the positive predictive value was 5% for DOB and 6%
for DIP (p 5 NS). Figures 1 and 2 show the Kaplan-Meier
survival curves according to the DIP and DOB results,
respectively. With DIP, the survival decreased progressively,
going from negativity to atropine, higher dose and low dose
positivity—the more pronounced step down being observed
with low dose positivity. With DOB, a similar pattern was
observed for low and higher dose positivity, whereas atro-
pine positivity (which was only observed in 27 patients) was
associated with a trend to a better survival than DOB
Table 1. Distribution of Cardiac Events in Relation to Stress Results
Cardiac Events
Cardiac Death (n 5 18)
Nonfatal Myocardial
Infarction (n 5 22)
Revascularization
(n 5 40)
DOB DIP DOB DIP DOB DIP
Negativity 8/242 6/253 13/242 13/253 21/242 22/253
3.3% 2.3% 5.3% 5.1% 8.6% 8.6%
Positivity (total) 10/218 12/207 9/218 9/207 19/218 18/207
4.5% 5.7% 4.1% 4.3% 8.7% 8.6%
Low dose 5/99 6/73 2/99 4/73 9/99 6/73
5.0% 8.2% 2.0% 5.4% 9.0% 8.2%
High dose 5/92 4/90 4/92 3/90 7/92 8/90
5.4% 4.4% 4.3% 3.3% 7.6% 8.8%
Atropine 0/27 2/44 3/27 2/44 3/27 4/44
0% 4.5% 1.1% 4.5% 1.1% 9.0%
DOB 5 dobutamine-atropine stress echocardiography; DIP 5 dipyridamole-atropine stress echocardiography.
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negativity (observed in 218 patients). Figures 3 and 4 show
the Kaplan-Meier survival curves stratified according to the
results of rest-stress WMSI variation during DIP and DOB
testing, respectively. With both stress, the survival was
progressively worse for larger variations in WMSI.
DISCUSSION
In patients at low-to-moderate risk of cardiac events,
pharmacological stress echocardiography with either dobut-
amine or dipyridamole allows an effective risk stratification
on the basis of the presence, timing, severity, and extension
of the induced ischemia. In particular, the extension and
severity of induced left ventricular dysfunction are the most
important predictors of cardiac related death among the
parameters describing the stress echocardiographic re-
sponse. When stratifying the positive response according to
timing severity and extension of ischemia, patients with a
positive test at low dose and/or with a high Delta WMSI
(.0.37) were at higher risk of cardiac death than were those
with a positive test at high dose and/or with a low Delta
WMSI (#0.37). These data are in agreement with previous
stress echocardiographic studies (19,20) and are consistent
with the linear relationship described between WMSI at
peak stress and extension and severity of underlying coro-
nary artery disease (21), which is a well-known angiographic
predictor of unfavorable prognosis (22). Both DIP and
Table 2. Univariate Predictors of Cardiac Events
Variables
HR (95% CI)
Cardiac Death
Cardiac Death
AMI
Cardiac Death
AMI
Revascularization
Resting WMSI 4.3 (1.5–11.9) 2.6 (1.6–4.9) 1.8 (1.0–3.1)
WMSI DIP 7.1 (2.6–19.5) 5.2 (1.3–21.6) 1.8 (1.0–3.0)
WMSI DOB 3.3 (2.8–11.5) 2.2 (1.1–4.3) 1.9 (1.7–3.1)
DIP6 2.9 (1.1–7.7) 2.3 (1.2–4.5) 1.2 (0.8–1.9)
DOB6 1.5 (0.6–4.0) 0.9 (0.4–2.2) 1.1 (0.7–1.7)
Delta WMSI DIP 2.6 (1.4–5.6) 4.9 (1.2–19.1) 2.2 (0.6–8.0)
Delta WMSI DOB 1.2 (0.1–3.8) 1.6 (0.3–7.5) 2.1 (0.8–1.4)
DOB Time 0.6 (0.3–0.9) 0.9 (0.6–1.1) 1.1 (0.8–1.3)
DIP Time 1.6 (1.1–2.3) 1.4 (1.1–1.9) 1.1 (0.9–1.4)
Ischemic segments DIP 1.2 (0.8–1.8) 1.7 (1.1–2.7) 1.1 (0.5–2.8)
Ischemic segments DOB 1.2 (0.8–1.8) 0.9 (0.5–1.3) 1.1 (0.8–1.4)
Gender 1.0 (0.3–3.5) 2.1 (0.6–7.1) 1.7 (0.8–3.4)
Age 1.0 (0.3–1.1) 0.9 (0.9–1.0) 1 (0.9–1.3)
History of angina 1.1 (0.7–2.3) 0.7 (0.4–1.4) 0.6 (0.4–1.0)
History of hypertension 1.0 (0.2–4.4) 2.3 (1.1–4.9) 0.9 (0.4–1.9)
Recent MI 1.5 (1.1–2.6) 0.9 (0.4–1.8) 1.4 (0.9–2.3)
Previous MI 1.4 (0.6–3.9) 1.1 (0.5–2.1) 1.1 (0.6–1.6)
History of PTCA 4.8 (2.4–22.2) 2.3 (0.7–7.6) 0.9 (0.3–3.1)
History of CABG 1.9 (0.4–8.5) 1.1 (0.2–4.9) 1.2 (0.5–2.8)
Antianginal therapy 1.1 (0.4–2.6) 1.8 (0.8–3.8) 1.2 (0.7–2.2)
AMI 5 acute myocardial infarction; DOB 5 dobutamine-atropine stress echocardiography; DIP 5 dipyridamole-atropine stress
echocardiography; MI 5 myocardial infarction; CABG 5 coronary artery bypass graft; WMSI 5 Wall-Motion Score Index;
PTCA 5 percutaneous transluminal coronary angioplasty.
Table 3. Stepwise Predictor of Cardiac Events
Variables Chi-Square p Value HR 95% CI
Stepwise predictors of cardiac death
WMSI DIP 14.62 0.0001 7.4 2.70–20.5
History of PTCA 5.31 0.02 5.8 1.6–20.4
Stepwise predictors of cardiac death and MI
DIP6 6.55 0.01 2.3 1.2–4.5
Stepwise predictors of cardiac death, MI, and
revascularization
WMSI DOB 7.5 0.005 1.9 1.2–3.1
DIP 5 dipyridamole-atropine stress echocardiography; DOB 5 dobutamine-atropine stress echocardiography; MI 5
myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
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DOB had a comparable prognostic value, with a marginal—
albeit statistically significant when cardiac death is consid-
ered—edge in favor of DIP. This may be due to a higher
number of diagnostic studies obtained with DIP than with
DOB in our series, in keeping with previous reports
(7,9–11).
In addition, when compared to dobutamine, dipyrida-
mole stress echocardiography positivity more frequently
occurs with prognostically unfavorable angiographic pat-
terns, such as plaque morphology of the complex type
(23–25) or in the presence of coronary occlusion and
coronary collateral circulation (24,26). Finally, positivity of
DOB—with negativity of DIP—is more often found in
patients with normal coronary arteries and in patients with
single-vessel disease of mild-to-moderate severity (12,25),
which define prognostically benign subsets.
Comparison with previous studies. The results of this
study confirm the data of two recent studies by Minardi et
al. (13) and Schro¨eder et al. (14) showing a similar prog-
nostic value of dipyridamole and dobutamine assessed in a
head-to-head comparison. However, these studies were
performed in a small sample size and needed the use of soft
cardiac events, such as revascularization procedures, to
document the prognostic power of the two tests. Our results
confirm and expand these previous observations. In fact, in
the present study, we assessed the prognostic yield of
dipyridamole and dobutamine in a large patient population,
with more than three years’ follow-up. This sample size
allowed us to document the prognostic value also using only
cardiac-related death as the end point in a subset of patients
at low-to-moderate risk for cardiac events (i.e., patients in
stable clinical conditions with relatively well-preserved left
ventricular function). In this subset of patients, the predic-
tive value of any diagnostic test is usually low, and this may
be the reason for the modest, but significant, value of the
relative risk of WMSI at peak stress in comparison to other
Figure 1. Kaplan-Meier survival curves event free of cardiac death in patients with negative and positive DIP. Survival is worse in patients
with positive DIP. In patients with positive DIP, progressive worse survival is identified with positivity after atropine, high dose and low
dose. DIP 1 low dose vs. DIP negative, p , 0.0001. Cardiac death (n 5 18); follow-up 38 6 21 months.
Figure 2. Kaplan-Meier survival curves event free of cardiac death in patients with negative and positive DOB. In patients with positive
DOB, progressive worse survival is identified with positivity after high dose and low dose, whereas patients with positivity after atropine
have a survival comparable to, or even better than, patients with DOB negativity (p 5 NS among all groups). Cardiac death (n 5 18);
follow-up 38 6 21 months.
1774 Pingitore et al. JACC Vol. 34, No. 6, 1999
Prognostic Value of Pharmacological Stress Echocardiography November 15, 1999:1769–77
studies that enrolled patients at higher risk for cardiac events
(22–29).
Study limitations. The prognostic yield of myocardial
viability was not assessed in this study. However, as docu-
mented in patients with recent myocardial infarction, rec-
ognition of myocardial viability during dobutamine is prog-
nostically important only for predicting unstable angina, but
not cardiac-related death. Viability, recognized with echo-
cardiographic methods, predicts cardiac death only in pa-
tients with severe left ventricular dysfunction (28), who were
excluded from the present study. Even in those patients, the
prognostic value of viability is outperformed by ischemia,
which is the major determinant of cardiac death, especially
if its severity is titrated through the WMSI (20,28–30).
In addition, the number of events in the study was
limited: only 18 cardiac deaths (3.9% of the total popula-
tion), despite the high number of enrolled patients (n 5
460) and the long duration of the follow-up (38 months on
average). Our population was clearly at low risk for cardiac
events, consisting of clinically stable patients, with preserved
left ventricular function, undergoing two stresses in a few
days. Any stress test for coronary artery disease looks much
better when faced with more extensive forms of disease,
with high incidence of events, and much less well in patients
with milder forms of disease, with low incidence of events
(31).
Conversely, the literature is inflated by studies in which
the assessment of the outcome is based on soft and patho-
physiologically heterogeneous events, such as revasculariza-
tion procedures, unstable angina, nonfatal reinfarction, and
cardiac death, in a population at high cardiac risk. However,
the goal of the present study was not to establish, in absolute
terms, the prognostic impact of the two tests in a well-
selected population, but rather to assess their relative prog-
nostic value in a garden variety of patients representing the
entire spectrum of population usually referred to the echo-
cardiography laboratory.
Moreover, our study was observational, not randomized,
and the decision of medical treatment over coronary revas-
cularization was made by the referring physician on the basis
Figure 3. Kaplan-Meier survival curves event free of cardiac death in patients stratified according to the results of rest-stress WMSI
variation during DIP (Delta DIP WMSI). The survival is progressively worse for larger variations on WMSI. Delta DIP WMSI . .37
vs. DIP negative, p , 0.0001; Delta DIP WMSI ..37 vs. DIP # .37, p , 0.004. Cardiac death (n 5 18); follow-up 38 6 21 months.
Figure 4. Kaplan-Meier survival curves event free of cardiac death in patients stratified according to the results of rest-stress WMSI
variation during DOB (Delta DOB WMSI). The survival is progressively worse for larger variations on WMSI. Delta DOB WMSI .
.37 vs. DOB negative, p , 0.005. Cardiac death (n 5 18); follow-up 38 6 21 months.
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of clinical, anatomical and stress echocardiographic find-
ings. This might have contributed to diluting the positive
predictive value of the stress test for hard end points as the
beneficial effects of ischemia-guided coronary revasculariza-
tion procedures are well known (29). However, most of our
patients with negative stress echocardiogram had no revas-
cularization procedures: thereby, the extremely high nega-
tive predictive value of the two tests is likely to reflect largely
a natural history follow-up. Our data also emphasize that
what is best for diagnosis is not necessarily ideal for
prognostic stratification: atropine coadministration, espe-
cially with dobutamine, did not efficiently stratify patients
with a higher risk in comparison to those with negative
results. When prognostic stratification is the main target,
more conservative protocols are probably warranted.
Clinical implications. Pharmacological stress echocardio-
graphic tests with dipyridamole and dobutamine are feasible
and safe. Both tests are able to predict cardiac death,
confirming—even in a population at low cardiac risk—the
prognostic power already documented in several subgroups
of patients (19,27–29), when the positive response is strat-
ified on the basis of timing, severity, and extension of
induced ischemia. The prognostic power of the two tests is
substantially similar, with a slight advantage for dipyrida-
mole. From a practical point of view, both tests should be
implemented—to be used as equally suitable alternatives in
the individual patient—for an optimization of diagnostic
and prognostic performance of a stress echocardiography
laboratory. There are three main reasons for this policy: 1)
Each patient being referred for stress evaluation may suffer
from relative or absolute contraindications to either stress
modality, or may undergo a therapy clearly lowering the
diagnostic potential of a given stress; 2) both dipyridamole
and dobutamine have excellent overall tolerability and fea-
sibility, as shown by large-scale multicenter experience
(32,33). Nevertheless, submaximal nondiagnostic tests do
occur in some patients because of side effects; therefore,
these patients may be referred to the other stress test; 3) for
the detection of minor, less extensive and severe forms of
coronary artery disease, a combined pharmacological stress
procedure may be needed at least when diagnosis, rather
than prognosis, is the mission of testing (34). It is important
that all stress echocardiographic laboratories become famil-
iar with both stress procedures for a flexible and versatile
diagnostic approach that may allow tailoring the best stress
test to individual patient needs (3).
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